85 related articles for article (PubMed ID: 22799348)
1. HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases.
Zhou XH; Tang LN; Yue L; Min DL; Yang Y; Huang JA; Shen Z
Asian Pac J Cancer Prev; 2012; 13(4):1457-61. PubMed ID: 22799348
[TBL] [Abstract][Full Text] [Related]
2. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma.
Shen Z; Yang ZF; Gao Y; Li JC; Chen HX; Liu CC; Poon RT; Fan ST; Luk JM; Sze KH; Li TP; Gan RB; He ML; Kung HF; Lin MC
Cancer Res; 2008 Jan; 68(2):404-14. PubMed ID: 18199534
[TBL] [Abstract][Full Text] [Related]
3. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
4. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
5. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
6. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
[TBL] [Abstract][Full Text] [Related]
8. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
[TBL] [Abstract][Full Text] [Related]
9. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
11. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
12. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
13. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
14. [The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro].
Xuan X; An C; Zhou C
Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):1-6. PubMed ID: 23327866
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
[TBL] [Abstract][Full Text] [Related]
16. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
18. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
[TBL] [Abstract][Full Text] [Related]
19. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
20. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]